BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22430635)

  • 1. Expression of CD200 on AML blasts directly suppresses memory T-cell function.
    Coles SJ; Hills RK; Wang EC; Burnett AK; Man S; Darley RL; Tonks A
    Leukemia; 2012 Sep; 26(9):2148-51. PubMed ID: 22430635
    [No Abstract]   [Full Text] [Related]  

  • 2. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.
    Le Dieu R; Taussig DC; Ramsay AG; Mitter R; Miraki-Moud F; Fatah R; Lee AM; Lister TA; Gribben JG
    Blood; 2009 Oct; 114(18):3909-16. PubMed ID: 19710498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic evolution of blast populations in pediatric acute myeloid leukemia.
    Pereira WO; Correia RP; Hamerschlak N; Bacal NS; Campregher PV
    Einstein (Sao Paulo); 2016 Mar; 14(2):288-9. PubMed ID: 26958979
    [No Abstract]   [Full Text] [Related]  

  • 5. Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function.
    Brady MT; Miller A; Sait SN; Ford LA; Minderman H; Wang ES; Lee KP; Baumann H; Wetzler M
    Leuk Res; 2013 Jul; 37(7):822-8. PubMed ID: 23628554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
    Yang T; Chen ZZ; Kolb HJ; Buhmann R
    Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.
    Coles SJ; Gilmour MN; Reid R; Knapper S; Burnett AK; Man S; Tonks A; Darley RL
    Leukemia; 2015 Sep; 29(9):1952-4. PubMed ID: 25748687
    [No Abstract]   [Full Text] [Related]  

  • 8. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
    van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34- blasts from acute myelogenous leukemia.
    Akashi K; Harada M; Shibuya T; Eto T; Takamatsu Y; Teshima T; Niho Y
    Blood; 1991 Jul; 78(1):197-204. PubMed ID: 1712640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.
    Schuster FR; Buhmann R; Reuther S; Hubner B; Grabrucker C; Liepert A; Reibke R; Lichtner P; Yang T; Kroell T; Kolb HJ; Borkhardt A; Schmetzer H
    Cancer Genomics Proteomics; 2008; 5(5):275-86. PubMed ID: 19129558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.
    Coles SJ; Wang EC; Man S; Hills RK; Burnett AK; Tonks A; Darley RL
    Leukemia; 2011 May; 25(5):792-9. PubMed ID: 21274000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute leukemia with t(8;21) can express T-lineage-associated markers.
    Orazi A; Kotylo P; Neiman RS
    Blood; 1992 Oct; 80(7):1855-6. PubMed ID: 1285763
    [No Abstract]   [Full Text] [Related]  

  • 13. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia.
    Weidmann E; Brieger J; Jahn B; Hoelzer D; Bergmann L; Mitrou PS
    Ann Hematol; 1995 Mar; 70(3):153-8. PubMed ID: 7718644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual attack on myeloblastic leukemic cells: the stimulus by B7 molecules matters.
    Schmitt A; Schmitt M
    Leuk Lymphoma; 2009 Mar; 50(3):315-6. PubMed ID: 19347721
    [No Abstract]   [Full Text] [Related]  

  • 15. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
    Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
    Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia.
    Narita M; Takahashi M; Liu A; Nikkuni K; Furukawa T; Toba K; Koyama S; Takai K; Sanada M; Aizawa Y
    Exp Hematol; 2001 Jun; 29(6):709-19. PubMed ID: 11378266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.
    Olsnes AM; Ryningen A; Ersvaer E; Bruserud Ø
    J Interferon Cytokine Res; 2008 May; 28(5):297-310. PubMed ID: 18547160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.
    Lepore M; de Lalla C; Gundimeda SR; Gsellinger H; Consonni M; Garavaglia C; Sansano S; Piccolo F; Scelfo A; Häussinger D; Montagna D; Locatelli F; Bonini C; Bondanza A; Forcina A; Li Z; Ni G; Ciceri F; Jenö P; Xia C; Mori L; Dellabona P; Casorati G; De Libero G
    J Exp Med; 2014 Jun; 211(7):1363-77. PubMed ID: 24935257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
    Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.